Summary
New Psychoactive Substances introduction  New Psychoactive Substances (NPSs) are psychoactive substances which are newly synthesised and/or newly available, designed to mimic the effects of 'traditional' illicit drugs and to be outside the scope of the Misuse of Drugs Act 1971. As they become brought under legal control, new ones have been manufactured often by slight changes in chemical composition.
 NPS use appears to be increasing nationally, while there has been a downward trend in the use of illicit drugs overall over the last decade.
 Patterns of use change; for example there is some evidence that the use of mephedrone increased until around 2012/13 and has fallen since then, while the use of nitrous oxide has increased in the last few years.
 The commonest routes of supply have been through head shops 1 and online, but new legislation outlaws the distribution of NPSs in this country. The impact of this on NPS use has yet to be seen.
New Psychoactive Substances key points
 Users of NPSs tend to be people who also use other illicit drugs, and different groups of NPS users have been identified including participants in the night-time economy, men who have sex with men (MSM), some groups of young adults, 'psychonauts' who experiment with psychoactive drugs, and vulnerable young people living in socially disadvantaged environments.
 There is limited evidence on the effects of NPSs but because they often contain a mixture of substances, or unknown substances, health effects can be unpredictable and idiosyncratic.
 Currently NPS users comprise only a small proportion of users of substance misuse services, although many users may not regard NPSs as substances with which they need help.
 There are no specific interventions to reduce demand for or manage dependence on NPSs and approaches used for other substances also apply to NPSs. These include information giving and resilience building for young people (including in schools), and psychosocial interventions using a stepped care approach to manage dependence.
 There is little information on NPS use in Suffolk. The proportion of substance misuse service users citing NPS use appears relatively low compared with other areas and the services in Suffolk do not perceive NPSs as a big problem.
 A survey of young people at New College, Ipswich found that almost a quarter had tried NPSs, and 11% reported using them frequently. Most of the respondents appeared to be aware that these drugs are no safer than illegal drugs and many said they would not use them even if recommended by a friend. However few appeared to be aware of local sources of information and advice about them.
 Anecdotal information suggests there may be particular concerns about substance misuse, including NPSs, in the Lowestoft area.
 There is evidence of a dramatic increase in use of synthetic cannabinoids ('Spice') in prisons over the last 5 years, including those in Suffolk.
 The Suffolk Recovery Forum has not encountered particular concerns about NPSs to date.
New Psychoactive Substances recommendations
 There should be a partnership approach to tackling all aspects of NPSs which is integrated into current substance misuse partnership arrangements. This should draw in a wide range of partners including various healthcare providers (both specialist substance misuse and non-specialist services), children's and adults' social care, teams working with those who are not in education, employment or training and Young Offenders, schools and colleges, youth services and various third sector organisations, the police, trading standards, and the criminal justice system including prisons and community rehabilitation. The Recovery Forum could develop into a partnership which takes a proactive approach to this work.  Consider what steps substance misuse services need to take to ensure they are accessible and seen as appropriate for users of NPSs, particularly considering risk groups such as young people, prisoners, MSM, and those from socially deprived areas.
Including development of outreach to target groups and environments where there is increased risk of NPS use such as clubs and festivals.
 Ensure that specialist services provide effective support for users of NPS. This should include; harm reduction where appropriate eg needle exchange for people who inject NPSs and interventions to reduce dependence for users of NPSs (who will often be multiple substance users). Any provision needs to underpinned by detailed information about these users, including demographic details, risk factors and interventions in order to determine and evaluate outcomes.
 Develop stronger links and pathways between specialist services and generic services such as sexual health, Accident and Emergency, paramedics and primary care. Ensuring that these workforces feel confident and competent to identify and deal with problems relating to NPSs (including acute reactions) and are able to provide information and to signpost people appropriately.
Most of the information collection and interviews for this needs assessment were carried out before the Psychoactive Substances Bill was published on 29 th May 2015.
What are New Psychoactive substances?
New Psychoactive Substances (NPSs) are substances which:
 are newly synthesised and/or newly available;
 are psychoactive and designed to mimic the effects of 'traditional' illicit drugs;
 may cause a threat to public health and/or the health of individuals;
 are designed to be outside the scope of the Misuse of Drugs Act 1971 (although many are now controlled under the Act), and not covered by the UN Drug Conventions;
 have become more widespread in use in the UK in the last 6-7 years.
'New' NPSs are constantly being manufactured, so there is no definitive list of substances, but their actions fall into 4 main categories, similar to the drugs they are designed to mimic; stimulant, hallucinogenic, depressant, or synthetic cannabinoids. Figure 1 gives examples of NPS by their effect. Although sometimes referred to as 'legal highs' many have been controlled under the Misuse of Drugs Act 1971 and many more are covered by Temporary Class Drug Orders which apply to specific compounds. The Psychoactive Substances Bill published on 29 th May 2015 will make it illegal to produce, distribute, sell or supply (although not to possess) 'any substance intended for human consumption that is capable of producing a psychoactive effect' (tobacco, alcohol and caffeine will be excluded). This effectively covers all NPSs which are available now or might be manufactured in the future. What is known about New Psychoactive Substance use in the UK and more widely? NPSs are predominantly used by those who also use other illicit drugs such as club drugs, either as a substitute or alongside other substances. Convenience, availability and lower prices are thought to be bigger drivers for NPS use than legal status alone, although legal status might influence new users. There is good evidence that some NPS users are prepared to take an 'unknown white powder' with no idea about its contents (Home Office 2014c)
A number of subgroups among whom NPS use is relatively high have been identified, including clubbers and other participants in the night-time economy, men who have sex with men, some groups of young adults, 'psychonauts' who experiment with psychoactive drugs, and vulnerable young people living in socially disadvantaged environments (Home Office 2014d).
NPSs are the primary drug of use among only a very small proportion of adults seeking treatment from substance misuse services, although around 5% cite use of any club drug.
Among young people in treatment use of mephedrone or club drugs is more common than among adults, and the commonest age for NPS use was 15. Reported mephedrone use increased up to 2012/13 in both adults and young people using services, but not significantly in 2013/14. Many NPS users do not recognise themselves as drug users and would not consider seeking help from services, and many who do come into contact with services who are using multiple substances would not consider they needed help with NPSs. An online survey looking at use of 'legal highs' in the UK included responses from 468 people who had ever taken 'legal highs', half of whom had used them first between the ages of 18 and 21, and a third when they were younger than that. There was a small proportion of very frequent users and many reporting only occasional use. Use with other substances (including alcohol) was common. Many users reported unpleasant physical symptoms associated with 'legal high' use and the majority considered that there were likely to be associated health risks. Most said they would go to a friend for help if they had a health problem due to taking a 'legal high', and only 40-50% said they would seek help from NHS health services; a greater number said they would look on the internet for help.
Intentions to use 'legal highs' again were influenced more by perceptions of safety, cheapness and easy availability, and views of friends, than by scientific information or news reports about their effects. Among people who had never used 'legal highs', the majority said they never would. An online survey was developed to try and gather views from local young people. There were 99 responses from young people at Ipswich college, most of whom were aged 16-18, although it is not possible to say how representative they are of young people in Ipswich as a whole. Almost a quarter said they had ever taken a 'legal high', and 11% were frequent users. Over two-thirds said they would not try one if offered it by a friend but 45% said they knew where to get 'legal highs', the internet, head shops or friends being the commonest sources. The majority said they did not feel very well informed about 'legal highs' but most did not think that 'legal highs' are safer than illegal drugs. Many appeared to be unaware of local potential sources of information about 'legal highs', and the majority would look on the internet (including FRANK) or media for more information if they wanted it.
What is the evidence base for interventions? What is best practice?
There are no specific approaches to reducing demand for NPSs compared to other substances, so generic approaches to providing information, reducing risk and building resilience apply to NPSs as to other substances and risky behaviours. A range of resources and guidance is available for educators and practitioners to support work in these areas, and schools are seen as a particularly important setting. There is likely to be a training need for many of those working with young people and other potential users who currently feel insufficiently informed about NPSs, including those in substance misuse services. A local integrated strategy for drug prevention should include action to tackle the use of NPSs.
A variety of approaches has been required to date to tackle the supply of NPSs, including preventing the activities of local retailers such as head shops through the use of Product in the UK to deal with problems due to NPS use, including increasing accessibility of services for NPS users, training for staff, better links and clear pathways between nonspecialist and substance misuse services, and better data recording.
Harm reduction approaches, although not a key part of current drugs policy, are also relevant to NPSs, particularly in relation to potential harms associated with injecting, reducing the risk of overdose and acute toxicity, and reducing risky sexual behaviour.
The above approaches are equally applicable to prisons and PHE, the National Offender Management Service and NHS England have identified the need to explore best practice in addressing the harms of NPSs within the prison setting as one of their current joint development priorities.
Working in partnership is critical for all these elements to be tackled successfully and many agencies need to be engaged in this work including various healthcare providers (both specialist substance misuse and non-specialist services), children's and adults' social care, teams working with Young Offenders and those who are not in education, employment or training, schools and colleges, youth services and various third sector organisations, the police, trading standards, and the criminal justice system including prisons and community rehabilitation.
What is in place in Suffolk at present?
A large number of services could potentially have an impact on reducing levels of NPS use, reducing the risk of associated harm, and supporting people to help them stop using NPSs. Police and Trading Standards have been working to reduce NPS supply in Suffolk for around three to four years and action has been taken against several outlets which were known to be supplying NPSs. Prison services take a number of approaches to reducing supply into prisons including intelligence-based searches, and additional netting was installed at HMP Highpoint to try and reduce the possibility of drugs being thrown in over the fence. 10. We are also interested in getting together a small group who would be able to discuss some questions about 'Legal Highs/ NPS' with us. If you would be interested in taking part in this, please provide your name and email address below. We will only use this to contact you about the group and will not pass on your contact details to anyone else
It was not possible to identify what is currently in place in schools across

Detailed findings of Suffolk online survey on legal highs
The survey was made available on the intranet at Ipswich college in the 2 weeks ending 22
May 2015.
There were a total of 99 respondents, 71 male (M) and 28 female (F). The questions, and the number of respondents to each (n) are shown on the charts.
The survey was also offered to a number of other settings including Lowestoft college, West Suffolk college, UCS, the YOS, the Prince's Trusts, and youth services Just 42, Level-2 and CYDS. However as there were a total of less than 10 responses across all the other settings these findings have not been presented. individual substances or modes of action separately (EMCDDA, 2015a) . New Zealand has aimed to reduce risk through an Act in 2013 which placed regulations on the manufacture and sale of NPSs, requiring producers to demonstrate that they are of 'low risk' to consumers before they are allowed to be sold, and that they are correctly labelled with active ingredients and health warnings. The impact of these different approaches has not been systematically evaluated. There is some evidence that NPS use has fallen in Ireland following the ban, although it still remains higher than other EU countries (see 'What is known about NPS use in the UK and more widely?') (European Commission, 2014).
The UK Government has been considering alternative approaches, based on the recommendations of the Expert Panel, and its Psychoactive Substances Bill was published on 29 th May 2015. This will make it illegal to produce, distribute, sell or supply psychoactive substances in Britain. It does not make possession alone a criminal offence (Home Office, 2015a).
The definition of psychoactive substances used in the Bill covers 'any substance intended for human consumption that is capable of producing a psychoactive effect'. As this includes substances such as tobacco, alcohol and caffeine, the Bill also includes exemptions for legitimate substances. It remains to be seen how this legislation will work in practice. Some commentators consider that it will push trade underground, and will have no effect on improving the safety of substances manufactured. NPS users commonly use the internet for sharing information about newer compounds and feeding back information about the effects of drugs, with many sites, blogs and discussion fora where such information is shared.
Development of New Psychoactive Substances
NPSs are often sold packaged and marketed as 'plant food', 'bath salts', 'research chemicals', 'incense' or 'herbal highs' and are typically labelled as 'not for human consumption' in an attempt to get round legal restrictions on products for human use. Lack of information about the contents is clearly not a deterrent for a significant number of users who are known to take substances when they have no idea what they consist of; for example, the Global Drug Survey found that 15% of all respondents and a fifth of those aged between 18 and 25 years had in the past 12 months used an 'unknown white powder' (Global Drug Survey, 2014a).
A number of different types of NPSs have been identified. The EMCDDA divides the market into the following categories (EMCDDA, 2015c):
Legal highs marketed in bright and attractive packaging. Sold openly in head/smart shops and online. Aimed at recreational users.
Research chemicals sold under the guise of being used for scientific research. Aimed at 'psychonauts' who explore the effects of psychoactive substances. Sold openly online.
Food supplements sold under the guise of being food or dietary supplements. Aimed at people wanting to enhance their body and mind. Sold openly in fitness shops and online.
Designer drugs passed off as drugs such as MDMA and heroin. Produced in clandestine labs by organised crime. Sold on illicit drug market by drug dealers.
Medicines that are diverted from patients or illegally imported into Europe. Sold on illicit drug market by drug dealers.
NPS Health harms
The relatively short time that NPSs have been available means that most evidence relates to short-term harms, with little information about longer-term effects. Even the short-term evidence is limited as little is known about toxicity for which medical advice is not sought or which does not lead to death. Within adult drug treatment services, those seeking treatment for NPS use comprise only a small proportion of the total treatment population, and the outcomes of treatment are generally positive (Home Office, 2014c).
While it is assumed that most of the NPSs being offered for sale have harms similar to the controlled drugs they have been manufactured to mimic, it is recognised that further research is needed to establish the full harms associated with these new drugs (Home Other research has identified a range of unpleasant physical effects reported as a consequence of using NPS, including nausea, heart palpitations, headaches, anxiety, feeling paranoid, hallucinations and agitation (eg. see Figure 10 ). Presentations can be idiosyncratic and atypical and professionals need to be aware of the possibility of NPS use in young people presenting with bizarre or unexpected behaviour (Winstock et al, 2012) .
Through their surveys of injecting drug users, Public Health England (PHE) have identified concerns about increases in injecting of mephedrone and about risky injecting behaviour among this group. They identify injecting of mephedrone as a recent practice among people who have previously injected other drugs, and among people who have switched from snorting mephedrone (Public Health England, 2014a). They found that in 2013, 8% (164 out of 2,077) of injecting drug users surveyed reported that they had injected mephedrone at some point during the preceding year. Among those who had injected mephedrone, 32%
reported having injected drugs with a needle or syringe that had previously been used by someone else, compared to 16% of those injecting other drugs.
